Baird Financial Group Inc. Decreases Stock Holdings in Zoetis Inc. $ZTS

Baird Financial Group Inc. reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 1.9% in the second quarter, according to its most recent filing with the SEC. The fund owned 459,254 shares of the company’s stock after selling 8,942 shares during the quarter. Baird Financial Group Inc. owned about 0.10% of Zoetis worth $71,621,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ZTS. Nova Wealth Management Inc. purchased a new position in shares of Zoetis in the 1st quarter worth $25,000. 1248 Management LLC bought a new position in shares of Zoetis in the 1st quarter valued at about $27,000. Saudi Central Bank purchased a new position in Zoetis in the first quarter worth about $29,000. REAP Financial Group LLC grew its position in Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after acquiring an additional 131 shares in the last quarter. Finally, NewSquare Capital LLC raised its position in Zoetis by 69.1% during the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 1.8%

NYSE ZTS opened at $120.33 on Friday. The stock has a market cap of $53.03 billion, a PE ratio of 20.26, a PEG ratio of 2.54 and a beta of 0.97. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $181.85. The company’s 50-day moving average price is $134.27 and its 200-day moving average price is $148.09. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The firm’s revenue for the quarter was up .5% on a year-over-year basis. During the same quarter last year, the business posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 2nd. Investors of record on Friday, October 31st were paid a $0.50 dividend. The ex-dividend date of this dividend was Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.7%. Zoetis’s dividend payout ratio is 33.67%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Argus reaffirmed a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. BTIG Research reissued a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research note on Wednesday. KeyCorp started coverage on shares of Zoetis in a research note on Thursday, November 20th. They set a “sector weight” rating for the company. Finally, Morgan Stanley cut their price target on shares of Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a report on Monday, November 10th. Six analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $178.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.